A study to evaluate the use of circulating tumour DNA to guide adjuvant chemotherapy on recurrence-free survival in patients with stage II Colon or rectal cancer.

Walter and Eliza Hall Institute0 个研究点目标入组 459 人开始时间: 2015年4月27日最近更新: 2021年1月5日

试验速览

暂无简介。

•1. Subjects with curatively resected stage II (T3-4, N0M0) colon or rectal cancer.
•2. Patients with rectal cancer will be eligible unless they have had pre-operative combined chemotherapy or radiotherapy, or are scheduled for post-operative combined chemotherapy and radiotherapy. All rectal cancer patients included in the trial must have had TME type surgery with negative (R0) resection margins.
•3. A representative paraffin embedded tumour sample is avaiable for molecular testing.
•4. Fit for adjuvant chemotherapy.
•5. ECOG performance status 0-2.
•6. Patients that are accessible for follow up.
•7. CT C/A/P within 8 weeks demonstrating no metastatic disease.

•1. History of another primary cancer within the last 3 years, with the exception of non-melanomatous skin cancer and carcinoma in situ of the cervix.
•2. Patients with multiple primary colorectal cancers
•3. Patients treated with neoadjuvant chemo-radiation.
•4. Medical or psychiatric condition or occupational responsibilities that may preclude compliance with the protocol.

发起方

Walter and Eliza Hall Institute